The Hologic Inc. TriMark 2S and CeleroMark 2S are titanium breast biopsy markers, containing a unique “hourglass” shape to help clinicians mark and independently identify multiple biopsy sites in the same breast.

The current Suros family of markers includes the ATEC TriMark and Suros CeleroMark biopsy site identifiers. These markers are compatible with the ATEC breast biopsy and excision system and Suros Celero ultrasound biopsy device, respectively. The standard TriMark identifier is a cylinder-shaped titanium pellet. The new 2S markers are half the size of the standard TriMark and can be used in conjunction with the current family of Suros biopsy site identifiers.

At least 70 percent of all breast biopsies require site identifiers with more than 800,000 used every year in the U.S. Single breast, multiple lesion biopsies are performed at different percentage rates depending on the imaging modality used in the biopsy. It is estimated that in a single breast, multiple biopsies are performed 10 percent of the time using ultrasound guidance, 5 percent in stereotactic X-ray and 40

Related Content

News | Breast Biopsy Systems

July 7, 2021 — GE Healthcare announced the installation of Serena Bright in five hospitals and radiology centers around ...

Time July 07, 2021
arrow
News | Breast Imaging

January 4, 2021 — Hologic, Inc. announced it has completed the acquisition of SOMATEX Medical Technologies GmbH, a ...

Time January 04, 2021
arrow
News | Prostate Cancer

According to the American Cancer Society, approximately one in nine men will be diagnosed with prostate cancer in their lifetime. It’s both the second most common cancer and second most common cause of cancer death in American men. Early detection is critical and can increase a man’s chances of survival.

Time August 20, 2019
arrow
News | Biopsy Systems

Dune Medical Devices has just completed the first in-man cases for Smart Biopsy, its percutaneous soft tissue biopsy device which leverages the real-time tissue characterization capability of its radiofrequency (RF) spectroscopy technology.

Time March 29, 2019
arrow
Technology | Interventional Radiology

The U.S. Food and Drug Administration (FDA) cleared the Ion endoluminal system from Intuitive Surgical Inc. to enable minimally invasive biopsy in the peripheral lung.

Time February 20, 2019
arrow
News | Prostate Cancer

Cambridge Consultants has partnered with Exact Imaging, makers of the ExactVu micro-ultrasound platform, as the two companies work to improve the way prostate cancer is visualized and detected. Cambridge Consultants is applying deep learning to high-resolution micro-ultrasound imaging to identify potential suspicious regions of tissue and inform urologists who may want to consider this additional data in their biopsy protocol. Early results show real promise, according to the companies.

Time February 12, 2019
arrow
News | Breast Biopsy Systems

A novel technique that uses mammography to determine the biological tissue composition of a tumor could help reduce unnecessary breast biopsies, according to a new study appearing in the journal Radiology

Time January 17, 2019
arrow
Videos | Radiation Oncology

Aadel Chaudhuri, M.D., assistant professor of radiation oncology, Washington University, St. Louis, Mo., explains his ...

Time November 07, 2018
arrow
News | Radiation Oncology

October 30, 2018 — A highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to ...

Time October 30, 2018
arrow
Technology | Breast Biopsy Systems

Leica Biosystems announced the U.S. launch of MammoPort, the first integrated specimen containment and transport system for breast tissue biopsies.

Time October 03, 2018
arrow
Subscribe Now